Scientists at the AAT-AD/PD conference debuted new detection methods for this biomarker, which they say distinguished healthy controls from MCI and AD.
This alternative approach to Aβ immunotherapy targets unlipidated, plaque-associated ApoE.
A new protocol robustly generates microglia-like cells from human stem cells. Disease-causing TREM2 mutations have little effect on some of their innate immune responses.
No benefit detected in double-blind trial with sham surgical controls.
Injecting 13C-labeled leucine intravenously, researchers tracked tau turnover in the human brain and cerebrospinal fluid for the first time.
In a small group of Swedish women, the fittest were nearly 90 percent less likely to develop dementia.
Kinesin mutations may disrupt organelle transport, putting motor neurons at risk.
What goes up can come down—rising tides of VILIP-1, neurogranin, and SNAP-25 ebb after onset of AD symptoms.
A large, prospective study confirms that PD unfolds more slowly in people with the G2019S LRRK2 mutation. The data will help scientists design and interpret clinical trials.
The knock-ins had no motor deficits or TDP-43 cytoplasmic inclusion. Instead, the animals had FTD-like behavioral problems.
A family of petite, RNA-directed nucleases offers a platform for finessing the transcriptome.
Rush University researcher recognized for longitudinal studies on aging, memory, and dementia.
Researchers report a link between sleepiness and accelerated Aβ buildup in the cingulate and precuneus of elderly adults without dementia.
Voyager Therapeutics announced positive interim results from a small, ongoing Phase 1b trial in people with advanced PD.
Representing each cell as a point, the atlas could help scientists measure brain-wide cell numbers and activity in health and disease.
No filters selected